Introduction
obesity, T2D, Gammaproteobacteria
OBESITY, INFLAMMATION, TYPE 2 DIABETES MELLITUS
Bariatric surgery (BS) is a highly effective therapy for patients with obesity and type 2 diabetes mellitus (T2D), and many mechanisms have been proposed for its metabolic benefits (Low concentrations of Firmicutes and an increase in the relative abundance of Gammaproteobacteria and In this scenario, we aimed to determine the changes in enteroendocrine hormones, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with obesity and T2D. Also, we studied the relationship between these changes and the metabolic improvement. The follow-up time was set at 12 months since this is the point where the weight reaches its nadir after bariatric surgery and then stabilizes (